Watch LYEL. Know when insiders buy.
One email the day a filing lands. Free.
Work order
54
WATCH · insiders 41, shorts 67
Insiders, 90 days
−$187K
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $352.1MP/E —DIV YIELD —FCF YIELD -38.04%REV TTM $27K −55.0%NET INCOME −$248.5MNET CASH —52W 11.61 – 38.60SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $4K | −50.0% | — | −$47.3M | −$44.8M | — | -1.92 | −$33.9M | $256K | −$34.2M | Aug 6 |
| Q1 2026 · Mar 31 | $2K | −71.4% | — | −$44.3M | −$24.2M | — | -1.10 | −$38.5M | $89K | −$38.6M | May 6 |
| Q4 2025 · Dec 31derived | $6K | −45.5% | — | −$127.6M | −$140.7M | — | -7.68 | −$32.3M | $304K | −$32.6M | Mar 12 |
| Q3 2025 · Sep 30 | $15K | −55.9% | — | −$37.3M | −$38.8M | — | -2.13 | −$28.6M | $62K | −$28.6M | Nov 12 |
| Q2 2025 · Jun 30 | $8K | −38.5% | — | −$47.1M | −$42.7M | — | -2.89 | −$34.5M | $168K | −$34.6M | Aug 6 |
| Q1 2025 · Mar 31 | $7K | +133.3% | — | −$57.4M | −$52.2M | — | -3.54 | −$54.7M | $246K | −$55M | May 6 |
| Q4 2024 · Dec 31derived | $11K | −15.4% | — | −$201.1M | −$191.9M | — | -14.40 | −$47.2M | $44K | −$47.3M | Mar 12 |
| Q3 2024 · Sep 30 | $34K | +36.0% | — | −$50.5M | −$44.6M | — | -3.48 | −$35M | $59K | −$35.1M | Nov 12 |
| Q2 2024 · Jun 30 | $13K | — | — | −$51.5M | −$45.8M | — | -3.59 | −$38.1M | $331K | −$38.4M | Aug 12 |
| Q1 2024 · Mar 31 | $3K | — | — | −$55.6M | −$60.7M | — | -0.24 | −$42M | $30K | −$42M | May 13 |
| Q4 2023 · Dec 31derived | $13K | — | — | −$59.5M | −$52.9M | — | -17.97 | −$40.6M | $25K | −$40.7M | Mar 12 |
| Q3 2023 · Sep 30 | $25K | — | — | −$59M | −$50.9M | — | -0.20 | −$37.7M | $195K | −$37.9M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $36K | — | −$269.4M | −$274.4M | -762355.6% | -16.06 | −$150M | $780K | −$150.8M | — | — |
| FY2024 · to Dec 31 | $61K | — | −$358.8M | −$343M | -562285.2% | -26.23 | −$162.4M | $464K | −$162.9M | — | — |
| FY2023 · to Dec 31 | $130K | — | −$247M | −$234.6M | -180486.2% | -18.70 | −$163.7M | $2.7M | −$166.4M | — | — |
| FY2022 · to Dec 31 | $84.7M | — | −$187.1M | −$183.1M | -216.2% | -0.74 | −$169.6M | $24.3M | −$193.8M | $0 | — |
| FY2021 · to Dec 31 | $10.7M | — | −$214.8M | −$250.2M | -2349.5% | -1.84 | −$126.2M | $65.5M | −$191.8M | $0 | — |
| FY2020 · to Dec 31 | $7.8M | — | −$211.9M | −$204.5M | -2636.3% | -15.69 | −$160.9M | $51.5M | −$212.4M | $11.8M | — |
Every number comes from Lyell Immunopharma, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.